Key Points
- Insider Stuart Rich bought 2,500 shares on Dec. 8 at $10.10 (total $25,250), bringing his holdings to 5,000 shares — a 100% increase — after multiple purchases earlier that week.
- TENX traded at $9.87 (up 0.5%) with a market cap of about $61.6M and a 52‑week range of $4.63–$10.55; analysts have a consensus Moderate Buy with an $18 target while several hedge funds (e.g., Millennium, Boothbay, Citadel) have recently increased stakes.
Tenax Therapeutics, Inc. (NASDAQ:TENX - Get Free Report) insider Stuart Rich acquired 2,500 shares of the stock in a transaction dated Monday, December 8th. The shares were bought at an average cost of $10.10 per share, for a total transaction of $25,250.00. Following the acquisition, the insider owned 5,000 shares in the company, valued at $50,500. The trade was a 100.00% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.
Stuart Rich also recently made the following trade(s):
- On Thursday, December 4th, Stuart Rich bought 2,500 shares of Tenax Therapeutics stock. The stock was bought at an average price of $9.20 per share, with a total value of $23,000.00.
- On Wednesday, December 3rd, Stuart Rich bought 1,500 shares of Tenax Therapeutics stock. The shares were bought at an average cost of $9.08 per share, with a total value of $13,620.00.
- On Tuesday, December 2nd, Stuart Rich purchased 1,000 shares of Tenax Therapeutics stock. The shares were bought at an average price of $9.01 per share, for a total transaction of $9,010.00.
Tenax Therapeutics Stock Up 0.5%
Shares of NASDAQ:TENX traded up $0.05 during trading on Thursday, reaching $9.87. The stock had a trading volume of 7,490 shares, compared to its average volume of 52,070. The stock has a fifty day simple moving average of $7.85 and a two-hundred day simple moving average of $6.69. Tenax Therapeutics, Inc. has a 52 week low of $4.63 and a 52 week high of $10.55. The firm has a market capitalization of $61.59 million, a price-to-earnings ratio of -8.73 and a beta of 1.55.
Tenax Therapeutics (NASDAQ:TENX - Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.33) by $0.93. On average, analysts forecast that Tenax Therapeutics, Inc. will post -0.88 EPS for the current year.
Institutional Investors Weigh In On Tenax Therapeutics
Hedge funds have recently made changes to their positions in the stock. ADAR1 Capital Management LLC grew its position in Tenax Therapeutics by 98.1% during the first quarter. ADAR1 Capital Management LLC now owns 68,741 shares of the specialty pharmaceutical company's stock worth $450,000 after buying an additional 34,048 shares in the last quarter. Virtu Financial LLC acquired a new position in Tenax Therapeutics in the 3rd quarter valued at approximately $92,000. Boothbay Fund Management LLC bought a new stake in shares of Tenax Therapeutics in the 3rd quarter worth approximately $2,680,000. Citadel Advisors LLC lifted its position in shares of Tenax Therapeutics by 318.1% in the 3rd quarter. Citadel Advisors LLC now owns 43,253 shares of the specialty pharmaceutical company's stock worth $329,000 after acquiring an additional 32,908 shares during the period. Finally, Millennium Management LLC boosted its stake in Tenax Therapeutics by 34.2% during the third quarter. Millennium Management LLC now owns 313,712 shares of the specialty pharmaceutical company's stock worth $2,387,000 after buying an additional 79,998 shares in the last quarter. Institutional investors own 1.67% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms have issued reports on TENX. Wall Street Zen raised Tenax Therapeutics to a "sell" rating in a research report on Saturday, October 25th. Guggenheim decreased their target price on Tenax Therapeutics from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, August 14th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Tenax Therapeutics in a report on Monday, December 1st. Finally, Piper Sandler initiated coverage on Tenax Therapeutics in a research report on Monday, September 8th. They issued an "overweight" rating and a $20.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Tenax Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $18.00.
Get Our Latest Analysis on TENX
Tenax Therapeutics Company Profile
(
Get Free Report)
Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
